The Trial Design Academy (TDA): For next generation HIV prevention research
As clinical trials in HIV prevention grow in complexity, advocacy for future trial design is more important than ever
Why Now?
Global rates of new infections remain high, even as the options for proven prevention increase. Trials to test new HIV prevention methods continue to be imperative, to ensure that communities in need of prevention will be able to find choices that work for them.
As daily and long-acting PrEP products roll out, innovative trial design is a focus and challenge for the field. Advocates and communities must play a central role in shaping future trial design. Their input is essential for both community acceptance of clinical trials and for trial results that advance the field. As trial designs grow more complex, this need is greater than ever.
About This Project
Launched in September of 2019, AVAC’s Trial Design Academy convenes HIV prevention advocates from across the globe to confront the technical challenges, engage with researchers, statisticians, product developers and regulators, and help shape the decisions to move the research agenda forward.
Ethical Guidance
HPTN Ethics Guidance Research — The updated guidance covers ethical considerations and their integration into the design and implementation of HIV prevention research.
Ethical Guidance in Focus — This blog post by AVAC’s Jeanne Baron highlights and compares what’s new in two updated guidance documents, from UNAIDS/WHO and the HPTN, both addressing where PrEP fits in HIV prevention trials